Vertex Pharmaceuticals (NASDAQ: VRTX) is a fast-growing pharmaceutical company that investors have been bullish on for years. The business generates billions in revenue from cystic fibrosis drugs, and it has been working on diversifying its portfolio to include a wider array of products. Today, the stock has a market capitalization of $115 billion — that’s […]
Tag: Vertex
Vertex Stock Sparks As Debate Rages Over Potential Blockbuster Pain Drug
Vertex stock advanced Tuesday as analysts debated the company’s pain drug, VX-548, with one saying it could eventually be worth up to $11.4 billion in sales. X The renewed pain drug debate follows Vertex Pharmaceuticals‘ (VRTX) first quarter report. The company beat forecasts and kept its outlook for the year. Vertex also noted it has […]
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
Vertex Pharmaceuticals (VRTX) will pay $4.9 billion to acquire immunological-focused biotech Alpine Immune Sciences (ALPN), the companies said late Wednesday. Alpine stock rocketed almost 21% on rumors of the deal.
Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here’s Why That’s a Smart Move.
Hot off the approval of its gene therapy for a pair of rare hereditary blood disorders, Vertex Pharmaceuticals (NASDAQ: VRTX) will soon have another therapy up for approval, and the financial implications are massive. But they’re not massive just because it stands to crank out billions in additional revenue. Instead, the plan is to shell […]
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here’s How You Can Invest
Vertex Pharmaceuticals (NASDAQ: VRTX) has a knack for finding profitable niches, and it looks like it’s on track to do so again in the field of pain relief. With the latest clinical-trial data pointing to possible development of a winning medicine, there’s reason to believe that more revenue could be on the way. But as […]
Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) already brings in billions of dollars annually, thanks to its cystic fibrosis (CF) drugs. The company recently proved it could expand beyond the specialty area when it won approval with partner CRISPR Therapeutics for a gene editing therapy for blood disorders. Next, Vertex is about to show that it can conquer […]